Navigation Links
Generex Announces Patent Award for its Core Vaccine Technologies in Japan
Date:2/1/2012

80% of breast cancers as well as a high percentage of prostate, ovarian, and other cancers.  AE37 represents the only HER2-based peptide vaccine currently being studied in a randomized trial and its use is not restricted to patients with a particular type of human leukocyte antigen (HLA) peptide.

About Breast Cancer

According to the American Cancer Society, more than 232,000 women will be diagnosed with breast cancer, and nearly 40,000 will die from the disease, in 2011.  For women whose cancer tests positive for increased quantities of the HER2, approved targeted therapies include trastuzumab (Herceptin®; Roche-Genentech).  However, only 25% of breast cancer patients have HER2 levels high enough to be eligible for Herceptin.  AE37 is positioned initially as an adjuvant therapy for at least 50% of breast cancer patients; i.e., those with low-to-intermediate levels of HER2 expression.

About Generex Biotechnology Corporation

Generex, the parent company of Antigen Express, is also engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T-helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others,
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. Generex Provides Additional Details for October 21st Live Video Webcast
9. Generex Announces $3.0 Million Capital Investment
10. Generex Announces Publication of Comparative Peptide Vaccine Studies in Peer Review Journal Demonstrating Superiority of AE37 and Presentation at the American Association for Cancer Research
11. Generex Oral-lyn™ Data to be Presented at Two International Scientific Symposia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer and ... production capability to serve biotechnology pharmaceutical clients. A ... continues to drive Nitto Avecia to enhance synthesis ... , In Fall 2014, Nitto Avecia first ... its Milford, MA facility, which is recognized as ...
(Date:4/30/2015)... 30, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... of biosimilar therapeutics including high value and difficult ... its previously announced underwritten public offering of 6,750,000 ... offering price of $15.50 per share. This includes ... their option to purchase up to 750,000 additional ...
(Date:4/30/2015)... FRANCE (PRWEB) April 30, 2015 ... and at http://www.lespausa.com , Phytomer’s DOUCEUR ... sensitive and reactive skin while battling the weakening ... This restorative cream is formulated with star ingredient ... via biotechnology in a complex of soothing minerals ...
(Date:4/29/2015)... 29, 2015 SPIE DSS, ... on the East Coast, reaffirmed its value last week ... developers, and industry suppliers to meet and advance the ... applications. , The event included 55 conferences in two ... sensing and imaging -- and an exhibition showcasing 382 ...
Breaking Biology Technology:Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Pfenex Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 2Phytomer introduces DOUCEUR INTEMPORELLE Restorative Shield Cream 3SPIE DSS provides venue for collaboration vital to research, applications advances 2SPIE DSS provides venue for collaboration vital to research, applications advances 3SPIE DSS provides venue for collaboration vital to research, applications advances 4
... Technology, Inc. ("ACT"; OTC Bulletin Board: ACTC ... announced today that Gary Rabin, the company,s interim chairman ... BIO-Europe Spring 2011 Conference, March 14-16, at the Milano ... scheduled for Wednesday, March 16, at 10:15 a.m. CET, ...
... --Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI ... medicine, modernized traditional Chinese medicine, branded generics and other ... Annual OC Growth Stock Conference from March 13 - ... California. Dr. James Jiayuan Tong, Chief Financial ...
... 2011 BioSpecifics Technologies Corp. (Nasdaq: BSTC ; ... products, today announced its financial results for the fourth quarter ... "2010 was an exciting year for the Company, but we ... to sales growth of XIAFLEX® in the U.S., as well ...
Cached Biology Technology:ACT Interim Chairman and CEO Gary Rabin to Present at BIO-Europe Spring 2011 Conference 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... This press relase is available in Spanish ... coloration of pickles, skin during fermentation may actually help ... a U.S. Department of Agriculture (USDA) study. ... when combined with tartrazine, a yellow food-coloring agent used ...
... of a portion of the tuberculosis genome that responds to ... Tiwari to zero in on a network of genes that ... cause tuberculosis (TB), Mycobacterium tuberculosis, can transition into a dormant ... system. A new report from Igoshin and Tiwari in this ...
... 2010 Science in Society Journalism Awards, sponsored by the National ... In the Book category, Susan Cohen and Christine Cosgrove for ... Medical Industry,s Quest to Manipulate Height" (Tarcher/Penguin). In ... Associated Press and the New York Times. Martha Mendoza and ...
Cached Biology News:Pickle spoilage bacteria may help environment 2Study finds possible 'persistence' switch for tuberculosis 2Study finds possible 'persistence' switch for tuberculosis 3Science in Society Journalism Award winners announced 2Science in Society Journalism Award winners announced 3
BD BioCoat Collagen IV 150 mm Culture Dishes...
...
...
... are derived from the Spodoptera frugiperda Sf21 cell ... in transfections, plaque assays, virus production, and protein ... that optimizes recovery of viable cells after thawing. ... Insect Cell Medium and can also be grown ...
Biology Products: